1,721,231 research outputs found
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. Reply to Dr. Ricceri letter
No full text
Cumulative Life Course Impairment in Melanoma and Nonmelanoma Skin CancerDermatological Diseases and Cumulative Life Course Impairment
No full textPatients with skin cancer remain at risk for disease progression or relapse for many years. Therefore, skin cancer may be considered a chronic, life-threatening disease. It could impact on patients lifestyles and social and professional activities. Although no direct study of cumulative life course impairment (CLCI) in skin cancer patients has been carried out, a few studies suggest that skin cancer may strongly impair quality of life and eventually determine a significant CLCI (melanoma more than nonmelanoma skin cancer). Obviously, the life course of patients with melanoma at an advanced stage of the disease may change considerably. A number of cancer-associated problems may determine a CLCI, including familial or professional changes and a reduction of life expectancy may eventually lead to social withdrawal and depressive disorders. Even patients with a low stage disease may experience an important impairment of quality of life and in some cases a CLCI. Some skin cancer patients may have physical and psychological after effects from their cancer surgery. Several patients complain about lymphedema, discomfort experienced from wearing surgical stockings, and diminished range of physical motion postsurgery. A few are concerned about their body image due to surgical scars, and they may consider changing their job position because of the supposed negative impact of scars in visible sites on their ability to perform their job. Some female melanoma survivors may have a reduced desire of having children in the future. Copyright © 2013 S. Karger AG, Base
Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis.
No full textBACKGROUND: Secukinumab is administered at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter. OBJECTIVES: To investigate the efficacy of secukinumab administered without the initial loading dose in patients with psoriasis. METHODS: This was a retrospective observational study including adult patients with psoriasis (n = 156) treated with secukinumab 300 mg administered either according to the labelled dose (n = 75) or without the initial loading dose (n = 81). Efficacy was evaluated by comparing the Psoriasis Area and Severity Index (PASI) 75 and PASI 90 response rates at week 8, 12, 16, 32 and 48. RESULTS: For patients who received the labelled dose vs. those who did not, PASI 75 response rates were achieved at week 8, 12, 16, 32 and 48 by 60% vs. 40% (P < 0·01), 72% vs. 61% (P < 0·01), 77% vs. 75%, 85% vs. 77% and 79% vs. 78%, respectively. PASI 90 responses were achieved at the same time points by 45% vs. 31% (P < 0·01), 49% vs. 40% (P < 0·01), 54% vs. 47%, 55% vs. 47% and 57% vs. 54% for those who received the labelled dose vs. those who did not, respectively. A greater proportion of patients receiving secukinumab without the loading dose discontinued treatment because of inefficacy (25% vs. 13%, P < 0·05), particularly those with body weight greater than 80 kg. CONCLUSIONS: Secukinumab administered without the loading dose is associated with a higher proportion of primary inefficacy, and achieved inferior results compared with the labelled dose at week 8 and week 12, but showed similar efficacy thereafter. What's already known about this topic? Secukinumab is an interleukin (IL)-17A inhibitor for chronic plaque psoriasis administered by subcutaneous injections at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter (maintenance dose). Dose adjustment is common in clinical practice, and can consist of dose reduction when a prolonged remission is obtained or a dose increase in order to improve efficacy. What does this study add? The efficacy of secukinumab administered without the initial weekly loading dose was significantly inferior compared with the labelled dose in the short term, but was similar after week 16 and up to week 48. A greater proportion of patients receiving secukinumab without the loading dose showed primary inefficacy, particularly those with body weight greater than 80 kg
Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.
No full textN
- …
